X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (34) 34
index medicus (34) 34
melanoma (26) 26
female (24) 24
oncology (23) 23
male (22) 22
melanoma - drug therapy (21) 21
cancer (19) 19
middle aged (19) 19
article (17) 17
aged (16) 16
melanoma - pathology (16) 16
adult (15) 15
ipilimumab (15) 15
research (12) 12
skin neoplasms - drug therapy (12) 12
treatment outcome (11) 11
tumors (11) 11
melanoma - immunology (10) 10
aged, 80 and over (9) 9
immunotherapy (9) 9
skin neoplasms - pathology (9) 9
antibodies, monoclonal, humanized - therapeutic use (8) 8
metastasis (8) 8
nivolumab (8) 8
patients (8) 8
safety (8) 8
abridged index medicus (7) 7
animals (7) 7
antineoplastic agents - administration & dosage (7) 7
antineoplastic agents - adverse effects (7) 7
antineoplastic agents - therapeutic use (7) 7
metastatic melanoma (7) 7
mice (7) 7
pembrolizumab (7) 7
programmed cell death 1 receptor - antagonists & inhibitors (7) 7
therapy (7) 7
care and treatment (6) 6
clinical trials (6) 6
drug therapy (6) 6
mutation (6) 6
neoplasm staging (6) 6
pd-1 (6) 6
pd-1 blockade (6) 6
young adult (6) 6
anti-pd-1 (5) 5
antibodies, monoclonal - administration & dosage (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antibodies, monoclonal, humanized - administration & dosage (5) 5
blockade (5) 5
cells (5) 5
chemotherapy (5) 5
disease-free survival (5) 5
melanoma - mortality (5) 5
neoplasms - drug therapy (5) 5
resistance (5) 5
survival (5) 5
adolescent (4) 4
antibodies, monoclonal - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
apoptosis (4) 4
b7-h1 antigen - metabolism (4) 4
biopsy (4) 4
braf (4) 4
cell biology (4) 4
cell line, tumor (4) 4
complications and side effects (4) 4
dermatology (4) 4
disease progression (4) 4
drug resistance, neoplasm (4) 4
lymphocytes (4) 4
lymphocytes t (4) 4
mek inhibition (4) 4
melanoma - genetics (4) 4
multidisciplinary sciences (4) 4
mutations (4) 4
neoplasm metastasis (4) 4
pathology (4) 4
patient outcomes (4) 4
prognosis (4) 4
protein kinase inhibitors - pharmacology (4) 4
proto-oncogene proteins b-raf - antagonists & inhibitors (4) 4
skin neoplasms - mortality (4) 4
solid tumors (4) 4
t cells (4) 4
analysis (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
antineoplastic agents, immunological - therapeutic use (3) 3
biology (3) 3
biomarkers, tumor - genetics (3) 3
brain neoplasms - secondary (3) 3
cancer therapies (3) 3
cd8 antigen (3) 3
chronic viral-infection (3) 3
criteria (3) 3
cytotoxicity (3) 3
dose-response relationship, drug (3) 3
drug administration schedule (3) 3
expression (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 373 - 377
Journal Article
Nature, ISSN 0028-0836, 08/2018, Volume 560, Issue 7718, pp. 382 - 386
Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1... 
CELLS | MELANOMA | PEMBROLIZUMAB | EXTRACELLULAR VESICLES | MULTIDISCIPLINARY SCIENCES | RESISTANCE | INDUCE APOPTOSIS | EXPRESSION | T-LYMPHOCYTES | NECK-CANCER | CHECKPOINT BLOCKADE | Exosomes - metabolism | Tumor Escape - drug effects | Prognosis | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Case-Control Studies | Neoplasm Metastasis | Immune Tolerance - immunology | Antibodies, Monoclonal, Humanized - pharmacology | Female | Immune Tolerance - drug effects | Tumor Escape - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - pathology | B7-H1 Antigen - immunology | Disease Progression | Antineoplastic Agents, Immunological - pharmacology | Xenograft Model Antitumor Assays | B7-H1 Antigen - metabolism | Animals | B7-H1 Antigen - blood | Antineoplastic Agents, Immunological - therapeutic use | Melanoma - immunology | Mice, Nude | CD8-Positive T-Lymphocytes - drug effects | Interferon-gamma - immunology | Melanoma - drug therapy | Cell Line, Tumor | Mice | Programmed Cell Death 1 Receptor - immunology | CD8-Positive T-Lymphocytes - immunology | Interferon-gamma - blood | Viral antibodies | Immunosuppression | Antibodies | Metastasis | Research | T cells | Properties | Biological response modifiers | Therapy | PD-1 protein | CD8 antigen | Lymphocytes T | Exosomes | Cancer therapies | Metastases | Skin cancer | Proteins | Vesicles | Lymphocytes | Immunotherapy | Immune system | Immunoglobulins | Melanoma | Immunosurveillance | T cell receptors | Patients | Immune checkpoint | Microscopy | PD-L1 protein | Ligands | Interferon | Head & neck cancer | Tumors | Apoptosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 134 - 144
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2014, Volume 32, Issue 30_suppl, pp. 120 - 120
Journal Article
Nature, ISSN 0028-0836, 05/2017, Volume 545, Issue 7652, pp. 60 - 65
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical... 
CRITERIA | MELANOMA | PEMBROLIZUMAB | IMMUNE CHECKPOINT BLOCKADE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | BRAF INHIBITORS | CHRONIC VIRAL-INFECTION | CANCER-THERAPY | IPILIMUMAB | EXHAUSTION | CD8-Positive T-Lymphocytes - cytology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - blood supply | Humans | Ki-67 Antigen - metabolism | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Melanoma - pathology | Phenotype | Antibodies, Monoclonal, Humanized - administration & dosage | Ki-67 Antigen - immunology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Melanoma - immunology | Melanoma - drug therapy | CD8-Positive T-Lymphocytes - metabolism | Female | Programmed Cell Death 1 Receptor - immunology | Antibodies, Monoclonal, Humanized - immunology | CD8-Positive T-Lymphocytes - immunology | Neoplasm Staging | Tumor Burden - immunology | Oncology, Experimental | Melanoma | Physiological aspects | Research | T cells | Tumors | Apoptosis | Cancer | Profiling | PD-1 protein | CD8 antigen | Medical services | Clinical trials | Lymphocytes T | Blood | Metastases | Immunology | Lymphocytes | Immunotherapy | Peripheral blood | Pretreatment | Medical research | Immunoglobulins | T cell receptors | Pharmacology | Patients | Pathology | Cell death | PD-L1 protein | Infiltration
Journal Article
JAMA, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1600 - 1609
Journal Article